Moleculin Biotech rises on completing enrollment for cancer drug study

Moleculin Biotech

21/09/2023 19:34

** Drug developer Moleculin Biotech's  MBRX.O  shares rise
6.6% to $0.40
    ** Company says it has completed enrollment in a mid-stage
study testing its experimental drug to treat soft tissue cancer
that has spread to affect the lungs
    ** Soft tissue sarcoma refers to cancer that begins in the
muscle, fat, fibrous tissue, blood vessels, or other supporting
tissue of the body
     ** MBRX expects data readout from early-stage portion of
the study in Q4 this year
    ** The drug candidate, annamycin, is the updated version of
an antitumor antibiotic called anthracycline - MBRX
    ** Annamycin has demonstrated a lack of heart damage that
arises from certain cancer treatments in some early-stage
studies - MBRX
    ** Including session moves, stock down ~62% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com))